Merck to Hold Third-Quarter 2019 Sales and Earnings Conference Call on October 29
01 Oktober 2019 - 12:55PM
Business Wire
Merck (NYSE:MRK), known as MSD outside the United States and
Canada, will hold its third-quarter 2019 sales and earnings
conference call with institutional investors and analysts at 8:00
a.m. EDT on Tuesday, Oct. 29. During the call, company executives
will provide an overview of Merck’s performance for the
quarter.
Investors, journalists and the general public may access a live
audio webcast of the call on Merck’s website at
http://investors.merck.com/investors/webcasts-and-presentations/default.aspx.
A replay of the webcast, along with the sales and earnings news
release and supplemental financial disclosures, will be available
at www.merck.com.
Institutional investors and analysts can participate in the call
by dialing (706) 758-9927 or (877) 381-5782 and using ID code
number 5635157. Members of the media are invited to monitor the
call by dialing (706) 758-9928 or (800) 399-7917 and using ID code
number 5635157. Journalists who wish to ask questions are requested
to contact a member of Merck’s Media Relations team at the
conclusion of the call.
About Merck For more than a century, Merck, a leading
global biopharmaceutical company known as MSD outside of the United
States and Canada, has been inventing for life, bringing forward
medicines and vaccines for many of the world’s most challenging
diseases. Through our prescription medicines, vaccines, biologic
therapies and animal health products, we work with customers and
operate in more than 140 countries to deliver innovative health
solutions. We also demonstrate our commitment to increasing access
to health care through far-reaching policies, programs and
partnerships. Today, Merck continues to be at the forefront of
research to advance the prevention and treatment of diseases that
threaten people and communities around the world - including
cancer, cardio-metabolic diseases, emerging animal diseases,
Alzheimer’s disease and infectious diseases including HIV and
Ebola. For more information, visit www.merck.com and connect with
us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA This news release of Merck & Co.,
Inc., Kenilworth, N.J., USA (the “company”) includes
“forward-looking statements” within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. These statements are based upon the current beliefs and
expectations of the company’s management and are subject to
significant risks and uncertainties. If underlying assumptions
prove inaccurate or risks or uncertainties materialize, actual
results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2018
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191001005138/en/
Media: Pamela Eisele (267) 305-3558
Investors: Peter Dannenbaum (908) 740-1037
Michael DeCarbo (908) 740-1807
Merck (NYSE:MRK)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
Von Apr 2023 bis Apr 2024